What were Risperdal (risperidone) sales in 2025?
I don’t have any 2025 Risperdal sales figures in the information provided here. If you share the source you’re using (for example, a company annual report table, an analyst dataset screenshot, or a country/market definition like “US only” vs “global”), I can help interpret it and convert it into a clean summary.
Are you looking for US sales, global sales, or company-reported revenue?
Risperdal sales can vary a lot depending on the scope:
- US prescription sales vs. global branded sales
- total brand demand vs. net sales (after rebates/discounts)
- calendar year 2025 vs. trailing 12 months ending in 2025
Tell me which one you mean and I’ll format the answer accordingly.
Who makes Risperdal and where would 2025 sales data usually come from?
Risperdal is a branded antipsychotic (risperidone). Public “sales” numbers in 2025 are typically reported through one of these channels:
- manufacturer disclosures (net product sales by brand)
- market research (prescription sales estimates)
- pharmacy/claims databases (often country-specific)
- filings where the drug is discussed in litigation or commercialization updates
If you name the dataset or company (e.g., J&J, a market research firm, or a specific filing), I can point you to how to locate the exact “2025 sales” line item.
How does 2025 sales relate to generic competition?
If your goal is to understand why branded Risperdal sales look low or flat in 2025, generic risperidone typically takes share from the branded product over time. The exact impact depends on:
- whether you’re looking at gross vs. net brand sales
- the market you’re measuring
- payer and formulary dynamics
Want sales by country, or just total?
If you reply with:
1) “US” or “global” (or a specific country), and
2) “brand sales” or “company net product sales,”
I’ll help you produce a concise 2025 figure and the most relevant context.
Sources: